GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Panacea Biotec PANACEABIO.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

360.65

+4.84%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Panacea Biotec

Its shares trade on NSE under the ticker PANACEABIO.NS. It has been listed since 25 September 1995. In the fiscal year to 31 March 2025, it reported revenue of ₹5.59bn and a net loss of ₹83.7m. At that date it held total assets of ₹12.90bn and shareholders' equity of ₹8.35bn.

Panacea Biotec Ltd. is a biotechnology company, which is engaged in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm manufactures a range of paediatric vaccines, including hexavalent vaccine, EasySixTM; pentavalent vaccine, Easyfive- TT and bivalent oral polio vaccine in India and market the same in India, as well as in international markets. The Company’s products include EasySix, Easyfive-TT, Easyfour-TT, EasyFourPol and Bi-OPV. Its pipeline candidates include BPBC, Hepatitis A, Covid-19 VoC mAb, NuVac-23, NuCoVac-11, Td and DengiAll. The firm is in the process of initiating phase III clinical trials for NucoVac-11, DengiAll and Td vaccines. Its operations are spread across different geographies in India. The firm has two manufacturing facilities located in Lalru, Punjab and Baddi, Himachal Pradesh, and two research and development (R&D) centers in Lalru, Punjab and New Delhi.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Sept 1995
Employees
1,093

Leadership

Pay as last reported

  • Dr. Rajesh JainExecutive Chairman of the Board, Managing Director, since 2025₹7.8m
  • Mr. Vinod GoelGroup Chief Financial Officer, Head Legal & Corporate Governance, since 2025
  • Mr. Ankesh JainCompliance Officer, Executive Director, Company Secretary, since 2016₹2.8m
  • Mr. Sandeep JainJoint Managing Director, Executive Director₹7.2m
  • Mr. Harshet JainWhole Time Director, since 2025
  • Dr. Sanjay TrehanDirector - Technical & Compliances
  • Mr. Mukul GuptaNon-Executive Independent Director₹250,000
  • Mr. Rajesh JainNon-Executive Independent Director
  • Mr. Krishan JalanNon-Executive Independent Director
  • Mr. Venkatesh SarvasiddhiNon-Executive Independent Director
  • Ms. Ambika SharmaAdditional Non-Executive Independent Director
  • Mr. Rajender SinghNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Panacea Biotec Ltd. manufactures pediatric vaccines like EasySix and Easyfive-TT in India.
  • The company operates two manufacturing facilities in Lalru, Punjab and Baddi, Himachal Pradesh.
  • Panacea Biotec has two R&D centers in Lalru, Punjab and New Delhi.

Weaknesses

  • The company's pipeline includes NucoVac-11, DengiAll, and Td vaccines in phase III trials.
  • Panacea Biotec Ltd. has 1,093 employees in its workforce.
  • The firm markets its products in India and international markets.

Opportunities

  • Panacea Biotec's pipeline candidates include BPBC, Hepatitis A, and Covid-19 VoC mAb.
  • The company is expanding its vaccine portfolio with NuVac-23 and NuCoVac-11.
  • Panacea Biotec is developing DengiAll for dengue fever treatment.

Threats

  • Panacea Biotec's products include EasyFourPol and Bi-OPV for polio vaccination.
  • The firm's manufacturing facilities are located in Lalru, Punjab and Baddi, Himachal Pradesh.
  • Panacea Biotec Ltd. has two R&D centers in Lalru, Punjab and New Delhi.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.